ScreenerHero

MNPRMonopar Therapeutics Inc.

NAS · US · Healthcare · Biotechnology · monopartx.com
107.72USD-13.02%Mkt Cap: 723.04M $P/E: —

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational onc…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap723.04M $
Enterprise Value610.15M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-13.72M $
Revenue/Share—
Last Price107.72 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees22
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS61023L1089
Valuation
P/E (Trailing)—
P/E (Forward)-56.00
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B5.69
EPS (TTM)-1.96
EPS (Forward)-1.98
52W Range
29.1882% of range124.42
52W High124.42 USD
52W Low29.18 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-9.95%
ROA-9.75%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-12.20M $
CapEx (TTM)—
FCF Margin—
FCF Yield-0.84%
Net Debt-134.09M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.00
Current Ratio33.56
Quick Ratio33.44
Book Value/Sh19.50 USD
Cash/Share20.01 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:5
Split DateAug 13, 2024
Analyst Consensus
Rating1.5 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)126.31 USD
Upside (mean)+17.3%
Target Range100.00 USD – 145.00 USD
$100.00+17.3% to mean$145.00
# Analysts13
Ownership
Shares Out.6.71M
Float4.48M
Insiders23.37%
Institutions95.02%
Short Interest
Short Ratio4.0d
Short % Float23.29%
Short % Out.15.90%
Shares Short1.07M
Short (prev mo.)1.52M
Technical
SMA 5099.77 (+8.0%)
SMA 20073.37 (+46.8%)
Beta1.51
S&P 52W Chg18.16%
Avg Vol (30d)281.58K
Avg Vol (10d)231.96K
Technical Indicators
RSI (14)48.3
MACD4.3114
MACD Signal5.7361
MACD Hist.-1.4247
BB Upper123.59 USD
BB Middle113.57 USD
BB Lower103.55 USD
BB Width17.64%
ATR (14)7.749 USD
Vol Ratio (20d)0.58x